Clinical features and outcomes in dogs with cholelithiasis

Symptomatic cases had higher alkaline phosphatase, gamma-glutamyl transferase, and alanine transferase activities than did incidental cases

To describe the clinical features and outcomes of dogs with cholelithiasis, focusing on cases that received medical treatment, and to identify patient factors that influenced decision-making for surgical or medical management.

Thirty-eight dogs with cholelithiasis were identified on abdominal ultrasonography (AUS).

Medical records of dogs with cholelithiasis on AUS between 2010 and 2019 were retrospectively reviewed. Cases were classified as symptomatic (n = 18) or incidental (n = 20) and divided into medically treated (n = 13), surgically treated (n = 10), and no treatment (n = 15) groups. Biochemical variables and cholelith location were compared between symptomatic and incidental groups using Mann-Whitney U and chi-squared tests, respectively. Survival times were compared using Kaplan-Meier survival analysis.

Symptomatic cases had higher alkaline phosphatase (P = .03), gamma-glutamyl transferase (P = .03), and alanine transferase (P = .02) activities than did incidental cases. A higher proportion of symptomatic cases (44.4%) had choledocholithiasis than did incidental cases (0%; P = .003). Seventy percent of surgically managed dogs, 7.7% of medically managed dogs, and 0% of nontreated dogs had choledocholiths at presentation. Seventeen dogs had follow-up AUS: cholelithiasis completely resolved in 4/8 medically treated, 5/7 of surgically treated, and 1/2 nontreated dogs. Median survival time was 457.4 days, with no significant difference between incidental and symptomatic dogs.

Medical treatment can be effective for management of cholelithiasis in dogs, with clinical presentation and cholelith location playing important roles in treatment decision-making.

“Clinical features and outcomes in 38 dogs with cholelithiasis receiving conservative or surgical management”. Frederik Allan, et al. J Vet Intern Med. 2021 Oct 29. doi: 10.1111/jvim.16284.

Like0

Dislike0

List
Add

Please enter a comment

Name *

Email address *

Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

Tag

Like0

Dislike0

EVENTS

Edrapublishing

About Us Authors Contact Us Legal Notes Privacy Search

Top

Clinical features and outcomes in dogs with cholelithiasis

Symptomatic cases had higher alkaline phosphatase, gamma-glutamyl transferase, and alanine transferase activities than did incidental cases

Comments

List

Add

Tag

More news

One Committed and Caring NC State Veterinary Student, So Many Choices

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Advancing the 3Rs: innovation, implementation, ethics and society

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Newsletter

News of interest

Advancing the 3Rs: innovation, implementation, ethics and society

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

One Committed and Caring NC State Veterinary Student, So Many Choices

Philanthropic Support and Specialized Surgery Saves Dog with Oral Tumor

EVENTS